Sustainability Report

Overview

The report highlights Tanvex BioPharma's 2024 U.S. FDA approval of its TX01 biosimilar, an important milestone for its affordable-medicine strategy. It also reports training for 141 employees totaling 1,288 hours. Environmental disclosures include 3,254 tCO2e of total emissions, alongside energy, water, and waste management initiatives.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services